What is the revenue and EPS growth rate for Encompass Health year over year?

What guidance did Encompass Health's management provide for the next earnings period?

What does Encompass Health do and what are its main business segments?

What is Encompass Health's gross profit margin?

What is Encompass Health's latest dividend and current dividend yield?

What is the market's earnings forecast for Encompass Health next quarter?

What were the key takeaways from Encompass Health's earnings call?

What factors drove the changes in Encompass Health's revenue and profit?

- **Revenue and EBITDA Growth**: Q3 revenue up 9.4% YoY, EBITDA up 11.4% to $300.1M, driven by volume and net revenue per discharge growth.
- **Strategic Expansion**: 2025 bed additions increased to 127 beds (from 110), with 2026-2027 targets raised to 150-200 beds. Small-format 24-bed hospitals planned for efficient growth.
- **Market Dominance**: 57% private room portfolio enables higher occupancy (mid-90%), outperforming industry averages. 14 announced new hospitals (690 beds) and 40+ active projects.
- **Financial Strength**: Free cash flow guidance raised to $730-810M. Share repurchases $82M YTD, dividend $0.19 declared. Net leverage 2x post $100M debt retirement.
- **Operational Excellence**: RN turnover 20.2%, below industry benchmarks. Labor costs stable, benefits inflation ~3.25%.
- **Medicare Growth**: Balanced payer mix growth (Medicare 4.4%, Medicare Advantage 4.8%, managed care 9.2%). VA Care Network volume up 26% YTD.


**【CEO Summary Section】**
- **Revenue Growth**: Q3 revenue increased 9.4% YoY, driven by a 5% rise in total discharges and 3.3% growth in net revenue per discharge. Adjusted EBITDA rose 11.4% to $300.1 million.
- **Patient Outcomes**: Discharge to community rate of 84.6%, discharge to SNF rate of 6%, and RN turnover of 20.2%, all exceeding industry averages.
- **Capacity Expansion**: Opened 3 new hospitals (40-bed in Connecticut, 50-bed in Florida) and added 39 beds. Q4 plans include 2 additional 50-bed hospitals and 37 bed additions.
- **Market Demand**: Medicare beneficiary population growing at 3% CAGR, with 77-year-old average patient age. IRF bed supply growth lags demand, underserving complex cases like stroke.
- **Pipeline**: 14 announced new hospitals (690 beds) and 40+ active projects, with 2025 bed additions increased to 127 beds (from 110) and 2026-2027 targets raised to 150-200 beds.

**【CFO Financial Commentary】**
- **Revenue and EBITDA**: GAAP net income $420 million, Non-GAAP EPS $1.08 (vs. $0.95 prior). Adjusted EBITDA up 11.4% to $300.1M, including $10.8M net provider tax revenue and $3M ERP conversion costs.
- **Cash Flow**: Q3 free cash flow $174.2M (down 8.2% YoY due to $55.8M working capital increase). Full-year guidance raised to $730-810M from $680-760M.
- **Share Repurchases**: 221,000 shares ($25M) repurchased in Q3, total $82M YTD. Dividend of $0.19 declared.
- **Leverage**: Net leverage 2x, with $100M senior notes retired in September.
- **Guidance Update**: 2025 net operating revenue $5.905-5.955B, EBITDA $1.235-1.255B, EPS $5.22-5.37.

**【Q&A Highlights】**
- **Bed Additions Strategy**: 2025-2027 bed additions increased to 127/150-200/150-200 beds, prioritizing high ROI bed expansions. Small-format 24-bed hospitals planned for efficient capacity growth.
- **Occupancy Targets**: 80%+ sustained occupancy triggers bed expansion. Private rooms (57% of portfolio) allow higher occupancy (mid-90%) vs. semi-private (under 90%).
- **Medicare Trends**: Balanced growth across Medicare (4.4%), Medicare Advantage (4.8%), and managed care (9.2%). VA Care Network volume up 26% YTD.
- **ER Conversion Impact**: ERP conversion smooth, minor bugs being resolved. No direct P&L impact, but long-term efficiency gains expected.
- **Washington Outlook**: No immediate concerns; CMS engagement positive. No impact on referral patterns from recent news.
- **2026 Outlook**: CapEx ~$580M midpoint, with bed additions driving growth. Labor costs stable, benefits inflation ~3.25%.


Encompass Health Corporation(EHC)-20251030-2025 Q3 Earnings call transcript

- **Revenue Growth**: 12% Q2 revenue increase to $1.46 billion, driven by 7.2% discharge growth.
- **EBITDA Expansion**: Adjusted EBITDA up 17.2% to $308.6 million, with CMS rate hike boosting Medicare revenue.
- **Free Cash Flow**: 2025 guidance raised to $705-$795 million, supported by tax benefits and share buybacks.
- **Quality Leadership**: Outperforming industry on discharge rates (8.5% to community, 5.8% to SNF) and patient satisfaction.
- **Expansion Momentum**: 5 new hospitals and 190 beds opening in H2, with 18 pipeline projects for future growth.

**【CEO Opening Remarks】**
- Q2 revenue increased 12% to $1.46 billion, driven by 7.2% discharge growth and 4.2% net revenue per discharge growth.
- Adjusted EBITDA rose 17.2% to $308.6 million, with 60-bed hospital openings in Florida and a 50-bed hospital in Daytona Beach.
- CMS 2026 IRF final rule includes a 2.7% net revenue per discharge increase, effective October 1, 2025.
- 2025 guidance updated to $5.88-$5.98 billion in revenue, $1.22-$1.25 billion in EBITDA, and $5.12-$5.34 in EPS.

**【CFO Financial Commentary】**
- Q2 free cash flow reached $186 million, up 30.5%, with year-to-date total of $408 million.
- 2025 free cash flow forecast revised to $705-$795 million, driven by bonus depreciation benefits.
- Net leverage at 2x, with $100 million unrestricted cash and $950 million available on revolving credit.
- Share buybacks of 232,000 shares ($24.7 million) and dividend increase to $0.19 per share.

**【Q&A Highlights】**
- **Occupancy & Expansion**: 76.6% occupancy (up 210 bps YoY), with 5 new hospitals opening in H2 and 190 beds added.
- **Quality Metrics**: Discharge to community rate 8.5%, SNF rate 5.8%, outperforming industry averages.
- **Payer Mix**: Managed care mix growth (18% from VA Community Care Network) and stable Medicare fee-for-service.
- **Labor Costs**: 3.4% FTE wage growth, 18% benefits expense increase due to high-dollar claims.
- **AI Integration**: Palantir partnership reduces administrative burden, e.g., 20-minute reduction in patient assessment documentation.
- **Strategic Expansion**: 18 pipeline projects, including new states like Connecticut, Utah, and Nevada.

Encompass Health Corporation (EHC) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: 10.6% YoY increase to $1.46 billion, driven by 6.3% discharge growth and 3.9% net revenue per discharge expansion.
- **Operational Efficiency**: EPOB at 3.4, lowest ever, with contract labor costs down 10% YoY.
- **Strategic Expansion**: 2025 bed additions raised to 100-120 beds, including 6 de novo hospitals and a 50-bed satellite.
- **Payer Mix Advantage**: Medicare fee-for-service growth outpaced Medicare Advantage, boosting margins.
- **Free Cash Flow**: Projected $620 million-$715 million for 2025, funding aggressive capacity expansion.


**【CEO Overview】**
- Q1 2025 revenue increased 10.6% to $1.46 billion, with adjusted EBITDA up 14.9% to $313.6 million.
- Same-store discharges grew 4.4%, driven by strong demand across geographies and patient types.
- Gross margin improved due to favorable payer mix (Medicare fee-for-service growth outpaced Medicare Advantage).
- 2025 bed expansion plans increased to 100-120 beds, with 6 de novo hospitals (300 beds) and a 50-bed satellite opening later this year.
- Promoted Pat Chickering to Chief Operating Officer to oversee operations amid rapid growth.

**【CFO Financial Details】**
- Q1 net operating revenue guidance raised to $5.85 billion-$5.925 billion.
- Adjusted EPS guidance updated to $4.85-$5.10, reflecting stronger-than-expected Q1 performance.
- Free cash flow for 2025 projected at $620 million-$715 million, driven by capacity expansions.
- Benefits expense per FTE increased 14% due to higher medical claims severity, but expected to moderate in H2.
- Contract labor costs declined 10% year-over-year, with FTEs as a percentage of total labor at 1.3%.

**【Key Q&A Highlights】**
- **Payer Mix Shift**: Medicare fee-for-service discharges grew faster than Medicare Advantage, contributing to 3.9% net revenue per discharge growth. This trend may not persist, but highlights reimbursement rate leverage.
- **Labor Efficiency**: EPOB (employees per occupied bed) at 3.4, lowest on record, due to higher occupancy (78.8%) and reduced reliance on contract labor.
- **Construction Costs**: No immediate impact from tariffs expected, as materials for 2025 projects already procured.
- **Demand Sustainability**: Aging population and underserved IRF market support long-term growth, with 10 announced de novo projects (500 beds) beyond 2025.


Encompass Health (EHC)-25 Apr 25-2025 Q1 Earnings call transcript

- **Record Financials**: Q4 revenue up 12.7%, EBITDA 13.6%, EPS 23.2%, with 7.8% discharge growth.
- **Expansion Acceleration**: 2025 to add 470 beds, 5 in Florida, targeting underserved Medicare markets.
- **MA Growth Momentum**: Medicare Advantage discharges +14.7% Q4, 5-year CAGR 11.6%, driven by improved outcomes and new market entry.
- **Free Cash Flow Power**: $690M annualized, enabling $63M shareholder returns in 2024 and 7 new hospitals.
- **Policy Watch**: Advocating for IRF network adequacy in MA and streamlined pre-authorization to reduce access barriers.

**【CEO Summary Section】**
- **Q4 Financial Highlights**: Revenue increased 12.7% to $1.4 billion, adjusted EBITDA rose 13.6% to $289.6 million, and adjusted EPS grew 23.2%. Total discharge growth was 7.8%, with same-store growth at 5.8%.
- **Strategic Positioning**: Focus on Medicare beneficiaries, targeting underserved IRF demand. 2024 saw 427 new beds added, with 2025 plans for 470 beds, including 5 Florida hospitals post-CON repeal.
- **Clinical Innovation**: Fall prevention model reduced fall rates by 30%, and ReACT 2.0 cut acute care transfers by 100 basis points. Discharge-to-home rate improved to 83.6%.

**【CFO Financial Commentary】**
- **Revenue Drivers**: 7.8% discharge growth and 4.2% net revenue per discharge increase. Medicare Advantage discharges grew 14.7%, with a 5-year CAGR of 11.6%.
- **Cost Control**: Bad debt expense decreased 200 basis points to 2.1%. SWB per FTE increased 6.4%, driven by merit raises and career ladder investments.
- **Free Cash Flow**: Q4 adjusted free cash flow was $190.5 million, up 103.7%, with full-year 2024 total of $690 million.
- **2025 Guidance**: Revenue $5.8-$5.9 billion, EBITDA $1.16-$1.20 billion, EPS $4.67-$4.96. Includes $18-22 million in preopening costs and $11-13 million in Oracle Fusion and joint venture expenses.

**【Q&A Key Takeaways】**
- **MA Growth Dynamics**: Same-store Medicare Advantage growth of 9.9% in 2024, driven by improved outcomes and reduced pre-authorization delays. Florida expansion highlights 13 new hospitals since 2021.
- **Capital Allocation**: 2025 CapEx ~$100 million for growth, with priority on beds. Free cash flow to be used for share buybacks and dividends post-2x leverage.
- **Policy Risks**: Monitoring new admin policies, advocating for IRF network adequacy in Medicare Advantage and streamlined pre-authorization.
- **Market Expansion**: South Carolina and North Carolina targeted for expansion, with underbedded markets and aging populations.
- **Clinical Efficiency**: RN turnover down to 20.4%, therapist turnover stable at 7.7%, supported by career ladders and compensation incentives.

EHC

EHC fundamentals

Earnings Call

You can ask Aime